NEW YORK (GenomeWeb) – Transgenomic and Horizon Discovery today announced they have entered into an OEM agreement, under which Transgenomic will incorporate Horizon Discovery's human genomic reference standards into its Multiplexed ICE COLD-PCR (MX-ICP) kits for research and clinical applications.
The MX-ICP technology allows simultaneous detection of multiple DNA mutations from a single sample.
"Incorporating Horizon's industry-leading controls into our MX-ICP kits supports our global commercialization campaign by providing customers and partners additional assurance of the exceptional performance of MX-ICP technology," Transgenomic CEO Paul Kinnon said in a statement.
Financial details of the agreement were not disclosed.
In 2014 the two firms collaborated on validating controls in the development of genetic diagnostic tests.